Not Yet RecruitingPhase 4ACTRN12608000293369

Intravenous Levetiracetam in the Acute Management of Seizures

Intravenous Levetiracetam in the Acute Management of Seizures in Epilepsy

Sponsor

Prof. David C. Reutens

Enrollment

20 participants

Start Date

Jun 1, 2008

Study Type

Interventional

Conditions

acute seizures

Summary

To examine the effectiveness and tolerability of Intravenous Levetiracetam in the acute seizure setting

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether an intravenous form of the anti-seizure medication levetiracetam can effectively manage acute seizures in epilepsy patients. It is for adults aged 18 or older with epilepsy who are admitted to the hospital for pre-surgical monitoring and experience seizures during that time.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Intravenous Levetiracetam will be administered in case of acute seizure (1000 mg over 5 minutes), for 1 dose only. Subjects will be observed and followed-up for the next 24 hrs following intravenous levetiracetam injection. Electroencephalographic recordings will be reviewed and subjects will be asked about adverse effects at 1, 12 and 24 hrs after intravenous administration of the agent.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000293369